Last updated: March 1, 2026
What is the Product?
NDC 62332-0315 is a proprietary drug marketed by Ascendis Pharma, marketed under the brand name "TransCon PTH." It is a sustained-release formulation of recombinant human parathyroid hormone (PTH) intended for hormone replacement therapy in hypoparathyroidism.
Market Overview
Therapeutic Area
Hypoparathyroidism is a rare endocrine disorder characterized by deficient or absent PTH, leading to hypocalcemia. The disease affects approximately 60,000 diagnosed patients in the U.S. (Meyer et al., 2018). Current standard treatments, including calcium and vitamin D supplements, are symptomatic and can lead to complications over long-term use.
Competitive Landscape
Key competitors include:
- Natpara (parathyroid hormone, recombinant) by Myriad Genetics (withdrawn from some markets)
- Off-label use of teriparatide (Forteo)
- New candidates under regulatory review or clinical trial phases
Regulatory Status
NDC 62332-0315 is in the late-stage development, with phase 3 trial data published in 2022 indicating significant improvements over existing therapies. While not yet FDA-approved, an accelerated approval pathway may be pursued based on clinical evidence, pending agency review.
Market Potential
The global market for hypoparathyroidism treatments was valued at approximately $550 million in 2022, projected to reach $1.2 billion by 2030 (GlobalData, 2023). The primary drivers include increased diagnosis rates, unmet needs for better dosage control, and regulatory incentives for orphan drugs.
Price Projections
Approved Drug Price Benchmarks
- Natpara, prior to market withdrawal, was priced at roughly $90,000 annually per patient (IQVIA, 2020).
- Teriparatide, as a comparator, varies between $20,000 and $50,000 annually, depending on dosage and formulary agreements.
Projected Pricing for NDC 62332-0315
Assuming successful FDA approval and commercialization, pricing is likely to be at a premium, reflecting its comparable efficacy and convenience. Estimated price range: $70,000 to $80,000 annually per patient.
Factors Influencing Price
- Clinical efficacy and safety profile improvements
- Manufacturing costs of sustained-release formulations
- Reimbursement landscape and payer negotiations
- Orphan drug designation, providing market exclusivity for seven years in the U.S.
Volume and Revenue Projections
- U.S. market penetration: 20% of the diagnosed population within five years of launch
- Estimated annual revenue in Year 3 post-launch: $150 million to $200 million
- Potential global revenue (excluding U.S.): $50 million to $75 million in initial markets
Risks and Uncertainties
- Pending regulatory review outcomes
- Competitive responses, including generic or biosimilar entrants
- Pricing pressure from payers and formulary exclusions
- Market acceptance among clinicians and patients
Key Economics and Policy Impacts
- Orphan drug designation may extend exclusivity
- Price controls or negotiations in major markets could influence final pricing
- Cost-effectiveness assessments by payers to determine reimbursement levels
Key Takeaways
- NDC 62332-0315 targets a niche but expanding market for hypoparathyroidism treatment.
- Pricing is expected to be in the $70,000-$80,000 range annually, based on existing market benchmarks and product positioning.
- Revenue potential hinges on regulatory approval, market access, and competitive dynamics.
- Significant uncertainties involve regulatory timing, payer acceptance, and potential market entry of biosimilars.
FAQ
1. When could NDC 62332-0315 reach the market?
Regulatory review is ongoing with potential approval expected within 12-24 months, depending on agency review timelines.
2. How does its price compare to existing therapies?
Expected to be priced higher than off-label treatments like teriparatide but comparable to Natpara prior to market withdrawal.
3. What is the patient population size?
Approximately 60,000 diagnosed patients in the U.S., with global estimates around 100,000 to 120,000.
4. What are the key risk factors affecting market success?
Regulatory delays, pricing negotiations, market acceptance, and competitive biosimilar entries.
5. How might policy changes impact pricing?
Price caps, reimbursement policies, and orphan drug incentives could alter the final market price and revenue potential.
References
[1] Meyer, J. et al. (2018). "Epidemiology of Hypoparathyroidism." Endocrine Reviews, 39(4), 538-550.
[2] IQVIA. (2020). "US Drug Price Analysis." IQVIA Institute for Human Data Science.
[3] GlobalData. (2023). "Hypoparathyroidism Treatment Market Report." GlobalData Healthcare.
